| Crude | Adjusted | ||
---|---|---|---|---|
Variable | HR (95%CI) | P value | HR (95%CI) | P value |
Age at initiation, year | ||||
 50-64 vs 17-49 | 1.16 (0.76 − 1.75) | 0.04 | 1.05 (0.68 − 1.62) | 0.84 |
 ≥65 vs 17-49 | 2.22 (1.19 − 4.15) | 0.04 | 1.75 (0.90 − 3.39) | 0.10 |
Male vs female patients | 0.61 (0.42 − 0.90) | 0.02 | 0.67 (0.42 − 1.06) | 0.09 |
Baseline eGFR < 60 vs ≥60 mL/min/1.73 m2 | 1.62 (1.15 − 2.27) | 0.006 | 1.28 (0.89 − 1.85) | 0.18 |
Hepatitis B | 1.02 (0.72 − 1.44) | 0.63 | 1.23 (0.78 − 1.95) | 0.37 |
Hepatitis C | 1.30 (0.90 − 1.87) | 0.02 | 1.26 (0.80 − 1.97) | 0.32 |
Alcoholism | 0.64 (0.36 − 1.14) | 0.74 | 0.79 (0.42 − 1.47) | 0.45 |
Decompensated liver cirrhosis | 1.24 (0.89 − 1.74) | 0.20 | 1.21 (0.84 − 1.74) | 0.32 |
HCC | 1.02 (0.73 − 1.44) | 0.29 | 1.06 (0.72 − 1.57) | 0.76 |
Diabetes mellitus | 2.32 (1.64 − 3.28) | <.0001 | 1.91 (1.32 − 2.77) | <.001 |
New onset diabetes mellitusb | 2.77 (1.96 − 3.90) | <.0001 | 2.34 (1.62 − 3.38) | <.0001 |
CNI prior use | 2.30 (0.73 − 7.27) | 0.15 | 2.27 (0.69 − 7.43) | 0.18 |
CNI use after | 0.69 (0.32 − 1.48) | 0.33 | 0.67 (0.29 − 1.54) | 0.35 |
SRL trough level < 3 months | 0.97 (0.91 − 1.03) | 0.30 | 1.01 (0.95 − 1.07) | 0.81 |